AKT1 and neoplasm: Although the above treatments lead to the effective inhibition primarily of AKT, they did not do the same for ERK phosphorylation in vivo, nevertheless, as noted, the MK2206 plus lapatinib combination is associated with greater anti-tumor responses both in vitro and in vivo than can be achieved with either agent alone.